CRVS — Corvus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Corvus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -43.2 | -41.3 | -27 | -62.3 | -15.3 |
| Depreciation | |||||
| Non-Cash Items | 9.3 | 12.5 | 6.54 | 38.4 | -21.2 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.24 | 1.41 | -3.59 | -1.65 | 3.58 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -36.7 | -27 | -23.9 | -25.4 | -32.8 |
| Capital Expenditures | -0.005 | -0.269 | -0.034 | — | -0.174 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 21.6 | -23 | 15.6 | -27.5 | -7.62 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 21.6 | -23.3 | 15.5 | -27.5 | -7.8 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 62.2 | 0 | 7.86 | 49 | 36.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 47 | -50.3 | -0.539 | -3.88 | -4.16 |